01
Clinical
GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC
Geneos Therapeutics is conducting a Phase I/IIa single-arm study of GNOS-PV02, a personalized neoantigen DNA vaccine, combined with plasmid-encoded IL-12 (INO-9012) and pembrolizumab in advanced hepatocellular carcinoma (HCC). The trial is currently active but not recruiting, focusing on the combination of DNA-based immunization with immune checkpoint inhibition.